Shareholders' Equity (Details) $ / shares in Units, $ in Thousands |
1 Months Ended | 3 Months Ended | 5 Months Ended | 12 Months Ended | |||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jan. 30, 2024
USD ($)
|
May 11, 2023
USD ($)
$ / shares
shares
|
Jan. 01, 2023
$ / shares
shares
|
Sep. 13, 2022
USD ($)
$ / shares
shares
|
Jun. 06, 2022
shares
|
May 11, 2022
$ / shares
shares
|
Apr. 04, 2022
USD ($)
$ / shares
shares
|
Dec. 20, 2021
$ / shares
shares
|
Nov. 03, 2020
$ / shares
shares
|
Oct. 31, 2020
$ / shares
shares
|
Jan. 22, 2020
$ / shares
shares
|
Jan. 19, 2020
₪ / shares
shares
|
May 31, 2023
USD ($)
|
Mar. 31, 2022
USD ($)
shares
|
Jan. 31, 2022
USD ($)
|
Jun. 30, 2021
USD ($)
shares
|
Oct. 31, 2023
$ / shares
shares
|
Dec. 31, 2023
USD ($)
$ / shares
shares
|
Dec. 31, 2022
USD ($)
$ / shares
|
Dec. 31, 2021
USD ($)
|
Jan. 25, 2023
shares
|
Jan. 19, 2020
$ / shares
|
Jun. 24, 2018
$ / shares
shares
|
|
Shareholders’ Equity [Line Items] | |||||||||||||||||||||||
Employees resulting in proceeds (in Dollars) | $ | $ 10 | $ 127 | $ 10 | $ 127 | |||||||||||||||||||
Aggregate amount (in Dollars) | $ | $ 13,587 | $ 1,000 | |||||||||||||||||||||
Granted options to purchase | 30,266 | ||||||||||||||||||||||
Exercise price | (per share) | $ 6.72 | $ 33.44 | ₪ 0.01 | ||||||||||||||||||||
Gross proceeds (in Dollars) | $ | $ 6,000 | $ 3,000 | |||||||||||||||||||||
Percentage of number of ordinary shares and warrants | 15.00% | ||||||||||||||||||||||
Warrants to purchase | 1,563 | 24,431 | |||||||||||||||||||||
Deducting issuance costs (in Dollars) | $ | $ 5,397 | ||||||||||||||||||||||
Purchase and sale of shares | 493,421 | 3,135 | |||||||||||||||||||||
Issuance of warrants | 493,424 | ||||||||||||||||||||||
Exercisable | 5 years | ||||||||||||||||||||||
Concurrent private placement (in Dollars) | $ | $ 3,500 | $ 3,000 | |||||||||||||||||||||
Warrants exercisable shares | 493,421 | ||||||||||||||||||||||
Purchase price per share (in Dollars per share) | $ / shares | $ 49.12 | $ 6.08 | |||||||||||||||||||||
Exceed ordinary shares | 291,544 | ||||||||||||||||||||||
Weighted average volatility | 70.00% | ||||||||||||||||||||||
Risk free interest rates | 1.40% | ||||||||||||||||||||||
Dividend yields percentage | 0.00% | ||||||||||||||||||||||
Weighted average life of the options | 5 years | ||||||||||||||||||||||
Term warrants | 3 years | 5 years 6 months | |||||||||||||||||||||
Purchase warrants | 1,563 | ||||||||||||||||||||||
Warrants exercise price (in Dollars per share) | $ / shares | $ 20 | $ 0.408 | |||||||||||||||||||||
Warrant exercisable per share (in Dollars per share) | $ / shares | $ 24 | ||||||||||||||||||||||
Weighted average fair value of options granted per share (in Dollars per share) | $ / shares | $ 0.13 | $ 0.48 | |||||||||||||||||||||
Unrecognized share-based payment expenses related to nonvested awards (in Dollars) | $ | $ 302 | ||||||||||||||||||||||
Expected to be recognized over the next | 2 years 9 months | ||||||||||||||||||||||
Recorded an expense (in Dollars) | $ | $ 5 | ||||||||||||||||||||||
Common Stock [Member] | |||||||||||||||||||||||
Shareholders’ Equity [Line Items] | |||||||||||||||||||||||
Converted ordinary shares | 30,266 | ||||||||||||||||||||||
Purchase warrants | 6,252 | ||||||||||||||||||||||
Minimum [Member] | |||||||||||||||||||||||
Shareholders’ Equity [Line Items] | |||||||||||||||||||||||
Weighted average volatility | 65.00% | ||||||||||||||||||||||
Risk free interest rates | 1.83% | ||||||||||||||||||||||
Share price (in Dollars per share) | $ / shares | $ 2.4 | ||||||||||||||||||||||
Maximum [Member] | |||||||||||||||||||||||
Shareholders’ Equity [Line Items] | |||||||||||||||||||||||
Weighted average volatility | 68.00% | ||||||||||||||||||||||
Risk free interest rates | 3.66% | ||||||||||||||||||||||
Share price (in Dollars per share) | $ / shares | $ 8.8 | ||||||||||||||||||||||
June 24, 2018 [Member] | |||||||||||||||||||||||
Shareholders’ Equity [Line Items] | |||||||||||||||||||||||
Purchase ordinary shares | 23,512 | ||||||||||||||||||||||
Share issued price per share (in Dollars per share) | $ / shares | $ 49.12 | ||||||||||||||||||||||
Vesting rights | These options expire 10 years after their grant date and vest over three years in nine tranches. One third of the options vested upon the first-year anniversary and the reminder vested in eight equal quarterly tranches over a period of two years thereafter. | ||||||||||||||||||||||
Options expire | 10 years | ||||||||||||||||||||||
Recorded an expense (in Dollars) | $ | 89 | ||||||||||||||||||||||
January 22, 2020 [Member] | |||||||||||||||||||||||
Shareholders’ Equity [Line Items] | |||||||||||||||||||||||
Granted options to purchase | 83,912 | ||||||||||||||||||||||
Exercise price | $ / shares | $ 49.12 | ||||||||||||||||||||||
Warrants to purchase | 9,322 | ||||||||||||||||||||||
Vesting rights | These options expire 10 years after their grant date and vest over three years in nine tranches. One-third of the options vested on September 18, 2020 and the remainder vest in eight equal quarterly tranches over a period of two years thereafter. | ||||||||||||||||||||||
Options expire | 10 years | ||||||||||||||||||||||
Recorded an expense (in Dollars) | $ | $ 163 | 380 | |||||||||||||||||||||
October 2020 [Member] | |||||||||||||||||||||||
Shareholders’ Equity [Line Items] | |||||||||||||||||||||||
Vesting rights | The options vest as follows: (1) options to purchase 17,400 ordinary shares vested in one tranche at the end of 12 months from October 13, 2020; and (2) options to purchase 34,801 ordinary shares will vest in the event that the Company generate a cumulative order backlog (as defined in the option agreement) in the amount of not less than $7,000 by the end of 18 months from October 13, 2020; (3) options to purchase 17,400 ordinary shares will vest in the event that the Company reaches a cumulative order backlog of $15,000 by the end of 24 months from October 13, 2020 (including the first cumulative order backlog); and all subject to him serving as the active Chairman of the Company’s Board at the time of vesting and were subject to an acceleration of 25% of his unvested options (i.e., 17,402) in the event that the Company effectuates an IPO. Accordingly, upon the completion of the IPO on April 4, 2022 (see Note 9B(4)), 17,402 were accelerated and considered fully vested. | ||||||||||||||||||||||
Recorded an expense (in Dollars) | $ | 133 | 332 | |||||||||||||||||||||
Options to purchase | 69,602 | ||||||||||||||||||||||
Exercise price (in Dollars per share) | $ / shares | $ 49.12 | ||||||||||||||||||||||
Options shares | 34,801 | ||||||||||||||||||||||
October 2020 [Member] | Minimum [Member] | |||||||||||||||||||||||
Shareholders’ Equity [Line Items] | |||||||||||||||||||||||
Options expire | 18 months | ||||||||||||||||||||||
October 2020 [Member] | Maximum [Member] | |||||||||||||||||||||||
Shareholders’ Equity [Line Items] | |||||||||||||||||||||||
Options expire | 24 months | ||||||||||||||||||||||
May 11 ,2022 [Member] | |||||||||||||||||||||||
Shareholders’ Equity [Line Items] | |||||||||||||||||||||||
Vesting rights | These options expire 10 years after their grant date and vest over three years in nine tranches. One-third of the options vested on May 11, 2023 and the remainder vest in eight equal quarterly tranches over a period of two years thereafter. | ||||||||||||||||||||||
Options expire | 10 years | ||||||||||||||||||||||
Recorded an expense (in Dollars) | $ | $ 96 | 61 | |||||||||||||||||||||
Options to purchase | 15,608 | ||||||||||||||||||||||
Exercise price (in Dollars per share) | $ / shares | $ 14.8 | ||||||||||||||||||||||
September 13,2022 [Member] | |||||||||||||||||||||||
Shareholders’ Equity [Line Items] | |||||||||||||||||||||||
Vesting rights | These options expire 10 years after their grant date and vest over three years in nine tranches. One-third of the options vested on September 13, 2023 and the remainder vest in eight equal quarterly tranches over a period of two years thereafter. | ||||||||||||||||||||||
Options expire | 10 years | ||||||||||||||||||||||
Recorded an expense (in Dollars) | $ | $ 51 | ||||||||||||||||||||||
Options to purchase | 31,500 | ||||||||||||||||||||||
Exercise price (in Dollars per share) | $ / shares | $ 14.8 | ||||||||||||||||||||||
Outstanding options | 46,964 | 46,021 | |||||||||||||||||||||
Reduced the exercise price (in Dollars per share) | $ / shares | $ 14.8 | ||||||||||||||||||||||
Additional fair value (in Dollars) | $ | $ 30 | ||||||||||||||||||||||
Warrant [Member] | |||||||||||||||||||||||
Shareholders’ Equity [Line Items] | |||||||||||||||||||||||
Exercise price | $ / shares | $ 0.003 | ||||||||||||||||||||||
Warrants to purchase | 1,563 | ||||||||||||||||||||||
Purchase warrants | 1,563 | ||||||||||||||||||||||
Warrants exercise price (in Dollars per share) | $ / shares | $ 12 | ||||||||||||||||||||||
Warrant exercisable per share (in Dollars per share) | $ / shares | $ 14 | $ 3.1 | |||||||||||||||||||||
IPO [Member] | |||||||||||||||||||||||
Shareholders’ Equity [Line Items] | |||||||||||||||||||||||
Issued units | 473,405 | ||||||||||||||||||||||
Unit description | Each unit included one ordinary share and one warrant to purchase one ordinary share at an exercise price of $33.44 per ordinary share. The warrants are exercisable at any time up to five years after the IPO. | ||||||||||||||||||||||
Over-Allotment Option [Member] | |||||||||||||||||||||||
Shareholders’ Equity [Line Items] | |||||||||||||||||||||||
Granted options to purchase | 71,011 | ||||||||||||||||||||||
Gross proceeds (in Dollars) | $ | $ 15,647 | ||||||||||||||||||||||
Private Placement [Member] | |||||||||||||||||||||||
Shareholders’ Equity [Line Items] | |||||||||||||||||||||||
Gross proceeds (in Dollars) | $ | $ 5,000 | ||||||||||||||||||||||
Aggregate of ordinary share | 493,421 | ||||||||||||||||||||||
Employees [Member] | |||||||||||||||||||||||
Shareholders’ Equity [Line Items] | |||||||||||||||||||||||
Dividend yields percentage | 0.00% | ||||||||||||||||||||||
Vesting rights | These options expire 10 years after their grant date and vest over three years in nine tranches. One-third of the options vested on November 3, 2021, and the remainder vest in eight equal quarterly tranches over a period of two years thereafter. | ||||||||||||||||||||||
Options expire | 10 years | ||||||||||||||||||||||
Recorded an expense (in Dollars) | $ | $ 45 | 46 | 62 | ||||||||||||||||||||
Exercise price (in Dollars per share) | $ / shares | $ 49.12 | ||||||||||||||||||||||
Granted options shares | 13,475 | ||||||||||||||||||||||
Employees [Member] | Common Stock [Member] | |||||||||||||||||||||||
Shareholders’ Equity [Line Items] | |||||||||||||||||||||||
Purchase ordinary shares | 209 | 2,591 | |||||||||||||||||||||
Chief Executive Officer [Member] | |||||||||||||||||||||||
Shareholders’ Equity [Line Items] | |||||||||||||||||||||||
Granted options to purchase | 68,739 | ||||||||||||||||||||||
Share issued price per share (in Dollars per share) | $ / shares | $ 14.8 | ||||||||||||||||||||||
Vesting rights | One-third of the options vested on June 18, 2024 and the remainder vest in eight equal quarterly tranches over a period of two years thereafter. | ||||||||||||||||||||||
Options expire | 10 years | ||||||||||||||||||||||
Recorded an expense (in Dollars) | $ | $ 22 | 20 | $ 12 | ||||||||||||||||||||
Options to purchase | 7,700 | 3,850 | |||||||||||||||||||||
Chief Executive Officer [Member] | October 2020 [Member] | |||||||||||||||||||||||
Shareholders’ Equity [Line Items] | |||||||||||||||||||||||
Vesting rights | (1) options to purchase 3,850 ordinary shares will vest on the condition that the Company generates, no later than October 12, 2022, a cumulative order backlog (as defined in the option agreement) in an amount not less than $10,000; and (2) options to purchase the remaining 3,850 ordinary shares will vest on the condition that the Company generates, no later than October 12, 2024 a cumulative order backlog (as defined above) in an amount not less than $20,000 (including the first cumulative order backlog); and all subject to him serving in his position at the time of vesting. | ||||||||||||||||||||||
Chief Executive Officer [Member] | May 11 ,2022 [Member] | |||||||||||||||||||||||
Shareholders’ Equity [Line Items] | |||||||||||||||||||||||
Options to purchase | 19,510 | ||||||||||||||||||||||
Officer [Member] | |||||||||||||||||||||||
Shareholders’ Equity [Line Items] | |||||||||||||||||||||||
Vesting rights | vest in twelve equal quarterly tranches over a period of three years | ||||||||||||||||||||||
Options expire | 10 years | ||||||||||||||||||||||
Recorded an expense (in Dollars) | $ | $ 12 | 4 | |||||||||||||||||||||
Options to purchase | 12,500 | ||||||||||||||||||||||
Exercise price (in Dollars per share) | $ / shares | $ 14.8 | ||||||||||||||||||||||
Officer [Member] | May 11 ,2022 [Member] | |||||||||||||||||||||||
Shareholders’ Equity [Line Items] | |||||||||||||||||||||||
Options to purchase | 68,395 | ||||||||||||||||||||||
Former Chairman [Member] | May 11 ,2022 [Member] | |||||||||||||||||||||||
Shareholders’ Equity [Line Items] | |||||||||||||||||||||||
Options to purchase | 33,277 | ||||||||||||||||||||||
Director [Member] | |||||||||||||||||||||||
Shareholders’ Equity [Line Items] | |||||||||||||||||||||||
Vesting rights | Such options will vest one-third following 12 months from the grant date of such options, second one-third following 24 months from the grant date and the balance following 36 months. | ||||||||||||||||||||||
Recorded an expense (in Dollars) | $ | $ 27 | 17 | |||||||||||||||||||||
Options to purchase | 14,974 | ||||||||||||||||||||||
Exercise price (in Dollars per share) | $ / shares | $ 14.8 | ||||||||||||||||||||||
Ordinary shares | 4,991 | ||||||||||||||||||||||
Officers and Employees [Member] | September 13,2022 [Member] | |||||||||||||||||||||||
Shareholders’ Equity [Line Items] | |||||||||||||||||||||||
Exercise price (in Dollars per share) | $ / shares | $ 49.12 | ||||||||||||||||||||||
Employees One [Member] | |||||||||||||||||||||||
Shareholders’ Equity [Line Items] | |||||||||||||||||||||||
Recorded an expense (in Dollars) | $ | $ 22 | $ 10 | |||||||||||||||||||||
Share-Based Payment Arrangement, Option [Member] | |||||||||||||||||||||||
Shareholders’ Equity [Line Items] | |||||||||||||||||||||||
Weighted average life of the options | 6 years | ||||||||||||||||||||||
Israel Railways [Member] | |||||||||||||||||||||||
Shareholders’ Equity [Line Items] | |||||||||||||||||||||||
Common stock issued | 24,431 | ||||||||||||||||||||||
Knorr-Bremse [Member] | Warrant [Member] | |||||||||||||||||||||||
Shareholders’ Equity [Line Items] | |||||||||||||||||||||||
Warrant exercisable per share (in Dollars per share) | $ / shares | $ 6.72 | ||||||||||||||||||||||
Chief Executive Officer [Member] | |||||||||||||||||||||||
Shareholders’ Equity [Line Items] | |||||||||||||||||||||||
Exercise price (in Dollars per share) | $ / shares | $ 49.12 |